Form 4: Nexalin CMO Owens Granted 1M Stock Options

Nexalin Technology's Chief Medical Officer, David Owens, was granted 1,000,000 stock options at an exercise price of $0.83, effective December 19, 2025.

Summary

• David Owens, Chief Medical Officer and a Director of Nexalin Technology, Inc. (NXL), was granted 1,000,000 stock options.
• The options have an exercise price of $0.83 per share.
• The transaction date for this grant was December 19, 2025.
• The options become exercisable on December 19, 2025, and expire on December 19, 2030.
• These options were granted under the 2023 Equity Incentive Plan.
• The grant is subject to shareholder approval to increase the Plan limit under NASDAQ Rules.
• Following this transaction, David Owens beneficially owns 2,484,809 derivative securities (stock options).

Sentiment

Score: 7

Explanation: The grant of stock options to a key executive is generally viewed positively as it aligns management's incentives with shareholder value creation, though it's a routine compensation event and does not indicate a significant change in company fundamentals.

Positives

• The grant of 1,000,000 stock options to Chief Medical Officer and Director David Owens aligns his long-term incentives with the company's performance and shareholder value creation.
• The options are granted at an exercise price of $0.83, providing a clear incentive for the executive to increase the company's share price above this level.

Negatives

• The grant is subject to shareholder approval to increase the 2023 Equity Incentive Plan limit under NASDAQ Rules, which introduces a condition to the full realization of the grant's intent.
• Potential future dilution for existing shareholders if the options are exercised, although this is a standard aspect of equity compensation plans.

Risks

• The effectiveness of the option grant is contingent upon shareholder approval to increase the 2023 Equity Incentive Plan limit under NASDAQ Rules.

Future Outlook

The grant of stock options is intended to incentivize long-term performance, but its full implementation is subject to future shareholder approval to increase the 2023 Equity Incentive Plan limit under NASDAQ Rules.

Industry Context

The grant of stock options is a common practice in the biotechnology and medical technology sectors for executive compensation, aiming to align the interests of key management with those of shareholders by tying a portion of their compensation to the company's stock performance.

Comparison to Industry Standards

• Equity incentive plans and stock option grants are standard components of executive compensation packages across the industry, including companies like Moderna, Pfizer, and Johnson & Johnson, which frequently use such mechanisms to attract, retain, and motivate top talent.
• The structure of this grant, with a defined exercise price and expiration date, is consistent with typical industry practices for performance-based compensation.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution if options are exercised, but also benefits from increased alignment of executive incentives with stock performance.
• Management/Executives: Directly impacts David Owens' long-term compensation and provides a strong incentive to enhance company value.

Next Steps

• Shareholder approval is required to increase the 2023 Equity Incentive Plan limit under NASDAQ Rules.

Key Dates

Recommendation

The filing reports a standard executive compensation event (stock option grant) which, while aligning management interests, does not provide new fundamental information to alter an investment thesis. A 'hold' recommendation reflects the lack of new material information to justify a 'buy' or 'sell' decision based solely on this filing.

Keywords

Nexalin Technology, NXL, Stock Options, Equity Incentive Plan, Insider Transaction, Form 4, David Owens, Chief Medical Officer, Executive Compensation